您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Imiquimod hydrochloride
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Imiquimod hydrochloride
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Imiquimod hydrochloride图片
CAS NO:99011-78-6
包装:100mg
市场价:500元

产品介绍

化学性质

Physical AppearanceA solid
StorageStore at -20°C
M.Wt276.76
Cas No.99011-78-6
FormulaC14H17ClN4
Solubility≥3.59 mg/mL in EtOH with ultrasonic; ≥5.54 mg/mL in DMSO with gentle warming and ultrasonic; ≥7.34 mg/mL in H2O with ultrasonic
Chemical Name1-isobutyl-1H-imidazo[4,5-c]quinolin-4(5H)-imine hydrochloride
Canonical SMILESCC(CN1C=NC2=C1C3=CC=CC=C3NC2=N)C.Cl
运输条件蓝冰运输或根据您的需求运输。
一般建议为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。

资料参考

Imiquimod hydrochloride is an immune response modifier that acts as a toll-like receptor 7 agonist and is commonly used topically to treat warts on the skin of the genital and anal areas.

试验操作

Cell experiment:[1]

Cell lines

Thioglycollate-elicited peritoneal cells from wild-type (C57BL/6) and MyD88-deficient mice

Reaction Conditions

101~ 104nM imiquimod for 24 h incubation

Applications

Imiquimod increased TNF-α and IL-12p40 production in IFN-γ-treated murine peritoneal macrophages in a concentration- and MyD88-dependent manner.

Animal experiment:[2]

Animal models

Female Hartley guinea pigs, 400 ~ 500 g

Dosage form

5 mg/kg

Administered intravaginally every 12 h for five days beginning 12 h after genital HSV-2 inoculation

Applications

Imiquimod (5 mg/kg, intravaginally, twice daily) reduced vaginal viral titer and lesion formation in a guinea pig model of genital HSV-2 infection. Imiquimod exhibited potent anti-HSV activityin vivodue to cytokine induction and enhancement of cell-mediated responses.

Note

The technical data provided above is for reference only.

References:

1. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nature Immunology, 2002, 3(2): 196-200.

2. Harrison CJ, Jenski L, Voychehovski T, et al. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antiviral Research, 1988, 10(4-5): 209-223.